Announcements Trials
Browse Landscape

Phase

Phase 2 46Phase 3 22Phase 1 7Phase NA 5Phase 4 4Phase 1/2 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Breast 1

Conditions

Breast Cancer Female 1

Interventions

Magnetic Resonance Spectroscopy 61Cyclophosphamide 57pembrolizumab 39fludarabine 38Radiotherapy 30Nivolumab 30Biopsy 27Metformin 23Fluorodeoxyglucose F18 22Bevacizumab 22Specimen Handling 21Temozolomide 18Cisplatin 18Radiosurgery 17Carboplatin 16Fluorouracil 15Paclitaxel 14Dexamethasone 14Radiation 13Gemcitabine 13Etoposide 13Rituximab 12Positron Emission Tomography Computed Tomography 12Letrozole 12Irinotecan 12gallium 68 PSMA-11 11durvalumab 11atezolizumab 11X-Rays 11Surgical Procedures, Operative 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Aromatase Inhibitors × Clear all
NCT04088032 2020-07-16

Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer

Stony Brook University

Phase EARLY_PHASE1 Withdrawn
BreastOther neoplasm

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡